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Abstract
Naphthoquinone  compounds  have  received  attention  for  their  ability  to  regulate
diseases from bacterial and parasite infections through to chronic human diseases.
Inflammation is widely considered to be at the root of many chronic diseases. The
reports  of  anti-inflammatory  activity  of  naphthoquinones,  including  vitamin  K1
(phylloquinone) and vitamin K2s (menaquinones), are of interest due to their very low
toxicity.  Most  of  the evidence for  the anti-inflammatory mechanisms of  vitamin K
suggests a role in the inhibition of the cell signalling complex nuclear factor kappa-B
(NF-κB).
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1. Introduction
From the 1960s through to the late 1990s, the F. Hoffman-La Roche laboratories in Basal,
Switzerland, were the centre of much of the innovative investigation into the role of vitamins in
physiology and pathophysiology. At that time, their laboratories were the leaders in exploring
newer concepts of biological actions of vitamins. For vitamin K, an exciting potential develop-
ment was in the analgesic and anti-inflammatory properties of naphthoquinone compounds;
an area that had not previously been considered [1, 2].
The explosion in the understanding of several areas since then, such as cytokine and chemokine
biology and physiology, molecular biology of signalling pathways and the genetic translation
of these signals, has facilitated the ability to explore molecular events in the cell. With these
innovations have come newer understandings of the role of vitamin K in physiology that go
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beyond the gamma-carboxylation of specific protein glutamyl residues in the vitamin K–
dependent proteins [3, 4].
2. Inflammation
The answer to the fundamental question ‘What is Inflammation?’ is, of course, complex. For
many years, discussion on inflammation revolved around the immune system and the ability
to distinguish ‘self’ from ‘non-self’. This required an understanding of the ancient ‘innate’
immune system and the ‘adaptive’ immune system. There has been a sea change in thinking
over the past three decades towards an appreciation of a primary role in the initiation of the
inflammatory response residing in the tissues [5].
The cells of a tissue, or tissues, in an organism are primed to respond when they are exposed
to an unusual stimulus. The response leads to a set of consequences, such as eicosanoid,
cytokine, chemokine release, alterations in metabolic activity and genes becoming activated
or switched off. These events can cause further cell activation either intrinsically within the
tissue or extrinsically such as drawing leukocytes into the tissue. The whole process would be
described as an inflammatory response.
The sequelae to the initiating events can lead to an expansion of the response, or the challenge
can be nullified and the tissues return to an original state. If the inflammatory state continues,
it can either persist as a long-term process, encountered as chronic diseases, or in severe cases,
the explosive changes overwhelm the organism leading to tissue necrosis and organ failure [6,
7].
There are reasonable arguments to suggest that normal ageing shares some similarities with
such chronic inflammatory disease [8, 9]. Indeed, the term ‘inflammaging’ was coined to
describe this possibility [9]. This case has also been made for specific diseases of ageing, such
as osteoporosis [10, 11].
There is also an innate anti-inflammatory process involving leukocytes and a number of
biological mediators, such as cytokines; however, with respect to vitamin K, this area of
research has not been the subject of focused research.
Irrespective of how we currently define inflammation, it is a biological process that serves a
purpose in the preservation of the organism, sometimes at the cost of some part of the whole,
but the government of the system can all too easily slip free of controls [12].
3. Vitamin K and inflammation
The pharmaceutical development of the anti-inflammatory role of activated protein C, a
vitamin K–dependent protein, is being established at the boundary of inflammation and
coagulation [13]. We will not consider this important subject here as, while vitamin K is
required for generation of the mature functional protein, it is the role of protein C as a serine
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protease that is central to the mechanism of limiting microthrombus formation in organ tissue
beds in sepsis [14].
Several important chronic diseases with an inflammatory background have been associated
with vitamin K deficiency. These include cystic fibrosis, inflammatory bowel disease, pan-
creatitis, chronic kidney disease and osteoporosis [15–19]. This review will not address the
relationship between vitamin K and these diseases, despite our ongoing interests. We have
instead focused our attention on the proposed cellular and molecular aspects of vitamin K in
regulating inflammation. With respect to this position, a subject that receives continuing
interest is the potential role of vitamin K in the amelioration of signal transduction pathways;
specifically, how vitamin K may be able to modulate the stimulus received at the surface of a
cell and the message transmission to the cell nucleus for interpretation and response.
3.1. Introduction to cell-to-nucleus signalling
Within cells, there are several primary pathways that are important in communicating the
exposure to an insult or injury. Early work on avian retroviruses, and in particular reticuloen-
dotheliosis virus strain T (Rev-T), identified an oncogene (v-rel) capable of transforming avian
lymphoid cells [20–22]. Once this oncogene had been characterized in avian systems, work
progressed quickly to look at mammalian homologues. This research revealed a mouse
homologue, c-rel, which was also found to have homologous character to the fruit fly Droso-
phila gene ‘dorsal’ [23–25]. The Drosophila dorsal gene is known to play a fundamental role in
dorsal-ventral development of the fly larvae, acting as a translocation factor in the cell nucleus
to regulate gene expression. Around the same time, another nuclear translocation factor, with
sequencing homology to these signalling factors, was discovered, which became known as
nuclear factor kappa-B (NF-κB) [26].
3.1.1. NF-κB
We present a greatly simplified overview of NF-κB signalling, and we recommend that
interested readers find some of the excellent review literature that has been published [e.g. 27–
34] in a complex and engrossing story.
NF-κB is present in nearly all cells and participates in a diverse range of biological functions
including inflammation, immunity, differentiation, cell growth, tumourigenesis and apoptosis,
that is, from birth to death of a cell. This pathway is a central conductor of the molecular
orchestra that is important for normal cell function, but it can become over-activated on a more
general level [35] or to a greater degree leading to tumourigenesis [36, 37].
We now know that NF-κB is a family of proteins that exist as hetero- or homodimers that have
been conserved from primitive organisms through to man [30]. The dimers are normally
quiescent in the cytosol of cells through the close association with a regulatory inhibitory
protein (IκB), first identified through an inspirational series of denaturation-renaturation
experiments [38]. NF-κB becomes activated by the removal of IκB from the complex, which
requires IκB phosphorylation by cytosolic kinase enzymes (IKK) [39]. The IκB protein is then
tagged, by ubiquitination, for degradation in the proteasome [34, 40]. A family of IκBs have
Anti-Inflammatory Actions of Vitamin K
http://dx.doi.org/10.5772/63891
155
now been identified and together with the IKK enzymes that phosphorylate the IκB proteins
and a scaffold IKK modulator (NEMO; IKKγ) [41], function at the heart of the system of NF-
κB activation and regulation.
Once dissociated from its inhibitory chaperone, NF-κB moves to the cell nucleus where it
recognizes specific nucleotide promoter sequences that activates a number of genes. This is
known for over 200 genes.
The complexity of the activation of NF-κB creates multiple tiers of regulatory control and,
therefore, also potential focal points for the development of therapeutic agents. Vitamin K and
its derivatives have been investigated for their ability to intervene in the activation of NF-κB.
3.1.2. NF-κB and vitamin K
There is evidence that vitamin K can regulate the activation of the NF-κB pathway. Other
signalling pathways also control cell functions and are, of course, important. Furthermore, in
the complex nature of multiple signalling pathways there is also considerable crosstalk
between these pathways [42]. There are also some reports that vitamin K has regulatory
functions on signalling pathways, other than NF-κB, such as the mitogen-activated protein
(MAP) kinases, but in this discussion, we focus on vitamin K and NF-κB.
Most of the research on vitamin K regulation of the NF-κB pathway has been done on cultured
cells, with a large element coming from researchers in Japan with a core interest in the
molecular mechanisms regulating cancer cells.
Hepatocellular carcinoma cells (HCC) are known to overexpress several oncogenes and also
down-regulate tumour suppressor genes [43, 44]. Vitamin K2, in the form of menaquinone-4,
has been investigated for its growth regulating effects in three hepatocellular cancer cell lines
[45]. Focussing on the proto-oncogenic expressed protein cyclin D1, which regulates the cell
cycle at the G1-S transition, and which is itself regulated by NF-κB [46]. These researchers found
menaquinione-4 inhibited both cyclin D1 mRNA expression and protein synthesis. In HCC
activated with phorbol ester or cytokines agonists in order to stimulate NF-κB signalling,
vitamin K was found to ameliorate cyclin D1 activation and NF-κB promoter binding was
inhibited. It was also noted that there was inhibition of the phosphorylation of IκB, with
suppression of IKK kinase activity.
The same research group has considered the effects of vitamin K2 on the expression of matrix
metalloproteinase (MMP) enzymes [47]. These enzymes are implicated in metastatic tumour
invasion [48]. HCC in culture were treated with phorbol ester and the expression of three MMP
proteins and their corresponding mRNA examined. The study found that menaquinone-4
suppressed basal and phorbol ester stimulated NF-κB activation, which translated into the
suppression of both MMP mRNA and protein expression levels. In these experiments, vitamin
K2 was also found to suppress the activation of the mitogen-activated protein (MAP) kinase
signalling pathway.
Two other publications from these researchers, again using HCC, explored the effects of
vitamin K2 to regulate cancer cell biology [49, 50]. In the first they examined potential
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modulation of HCC growth by the anti-cancer therapeutic 5-fluorouracil, through inhibition
of cyclin D and innate activated NF-κB signalling. Their other study investigated the effects of
vitamin K2 on protein kinase C (PKC), a known mediator in multiple stimulated cell responses
in HCC [51]. Working in an adjunctive role with 5-fluorouracil, menaquinone-4 was found to
augment the growth inhibition induced by 5-fluorouracil alone, this being most effective when
the cells were pretreated with vitamin K2. From the discussion above on the NF-κB pathway,
any finding of an inhibition of kinase activities may be expected to have an effect on NF-κB
activation. In their PKC study, these researchers found delineation in the response to vitamin
K2 between the PKC isoforms. All the PKC isozymes were found to be involved in NF-κB
activation, but vitamin K2 inhibited the NF-κB activation through its actions on only two of
these, PKCα and PKCε. This selectivity was not investigated further.
The above discussion focuses on directed inflammatory stimuli using laboratory reagents;
however, there are numerous agents that can promote an inflammatory response, including
infective agents like viruses and bacteria. We are all exposed to bacterial endotoxins or
lipopolysaccharides (LPS), every day and without much effect, but when these endotoxins are
shed in an injured tissue, the results are registered quickly through cell surface Toll-like
receptors that trigger, among other signalling pathways, NF-κB [52].
A potent, and key, cytokine in the response to endotoxin insult is interleukin-6 (IL-6) [53]. Up-
regulation of IL-6 synthesis is under NF-κB control [54], and this cytokine can feed back into
the inflammatory response. This feedback is achieved via interaction with its own specific cell
surface receptor that activates the Janus kinase (JAK) signal transducer and activator of
transcription 3 (STAT3) pathway [55].
We have reported a vitamin K-mediated suppression of IL-6 release in LPS-challenged primary
human fibroblast cell cultures [56]. This investigation found that vitamin K2, in the form of
menaquinone-4, was a more potent anti-inflammatory compound than vitamin K1 in this
primary cell system.
Other cell and animal experiments have looked at the possible regulation of inflammation by
vitamin K inhibition of IL-6 release following endotoxin challenge. These include studies using
germ-free rats, THP-1 human monocyte-like cells and murine RAW264.7 macrophage-like
cells [57, 58] and have noted a significant reduction in the LPS-stimulated cellular IL-6 mRNA
levels. In the vitamin K supplemented animal experiments, there was a suppression of the
hepatic mRNA levels of the inflammation response protein macrophage migration inhibitory
factor (MIF), compared to animals fed a vitamin K-deficient diet. This study also found that
supplementation with vitamin K1 also caused a rise in hepatic tissue menaquinone-4 levels
[57]. Extension of these in vivo findings in the two cell lines, THP-1 and RAW264.7, demon-
strated that the suppression of LPS-stimulated IL-6 mRNA by vitamin K2 was consistent with
inhibition of NF-κB activity via the restricted phosphorylation of IKK kinases [58]. These
researchers also questioned whether these events involved a classical vitamin K gamma-
carboxylation-mediated process; co-culture experiments with warfarin found that these
inhibitory effects of vitamin K on NF-κB were independent of vitamin K–dependent protein
gamma-carboxylation [58]. The widely appreciated role of IL-6 in inflammatory diseases
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makes the findings of an inhibitory activity for vitamin K in IL-6 release an increasingly
attractive prospect.
One of the dominant areas of NF-κB understanding is in osteoclastogenesis. Activation of this
pathway in hematopoietic stem cells by receptor activator of nuclear factor kappa-B ligand
(RANKL), a member of the tumour necrosis ligand superfamily, has been found to be a
prominent initiator of osteoclast formation [59, 60]. Once precursor cells have been positioned
to develop into osteoclasts by RANKL, NF-κB further facilitates development through
inhibition of apoptosis [61].
Menaquinone-7, a more hydrophobic homologue of vitamin K2 than menaquinone-4, has been
found to limit rat osteoclast formation under various challenges [62]. Later studies determined
that the anti-osteoclastogenic actions of menaquinone-7 were mediated by the inhibition of
NF-κB [63].
A central feature of all research on the role of vitamin K in the inhibition of NF-κB is the high
concentrations that were required to demonstrate an effect of the order of 10−5 to 10−4 M in cell
culture and pharmacological dosing in animal experiments. The relatively high concentrations
required suggests that the anti-inflammatory activities of vitamin K are not working through
specific receptors and it is, therefore, more likely that the anti-inflammatory activities are due
to other characteristics of vitamin K.
3.2. Other anti-inflammatory vitamin K–like compounds
Some supporting data on the potential for vitamin K to serve a physiological anti-inflammatory
role can be found in studies using other vitamin K–like compounds. Below, we focus on two
compounds that have a common 2-methyl-1,4-naphthoquinone functional group as vitamin
Figure 1. The molecular structures for phylloquinone, vitamin K1; menaquinone vitamins, vitamins K2; menadione,
vitamin K3; NaQuinate, the 7-carbon carboxylic acid catabolite derived from all forms of vitamin K1 and K2.
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K1 and K2, namely menadione, or vitamin K3, and a 7-carbon carboxylic acid catabolite of
vitamin K, NaQuinate (Figure 1).
3.2.1. Menadione and inhibition of inflammation
Menadione, or vitamin K3, was for a long time considered to be a synthetic compound.
Research that started in the 1990s demonstrated that menadione was an important derivative
from vitamin K1 that was converted in the rat to make the vitamin K2 congener menaqui-
none-4 [64–67]. The enzyme responsible for the conversion of menadione to menaquinone-4,
UBIAD1 [68] has a wide distribution across species and likely plays a significant role in the
vitamin K status of many animals (see chapter by O'Neil et al., this volume).
Seminal work on the amelioration of chronic inflammatory arthritis in a rabbit antigen-induced
model found a pronounced anti-inflammatory effect in animals receiving oral menadione. This
was related to a significant decrease in synoviocyte glucose-6-phosphate dehydrogenase
activity in the treated rabbits [69] and reduced macrophage numbers in the treated joint
(personal communication). It is unclear if this was due to a direct effect on the joint tissue as a
latter study using menadione-epoxide in the same model was also found to have a significant
anti-inflammatory activity [70]. Alternative explanation for these effects includes the possible
conversion of these menadione and menadione-epoxide molecules into vitamin K2, as
menaquinone-4, through the action of UBIAD1 [68]. This would be consistent with lapine
caecal bacterial conversion due to known coprophagy in this species (see chapter by O’Neil et
al., in this volume).
Menadione has also been shown to inhibit NF-κB translocation to the nucleus in tumour
necrosis factor (TNF)-α stimulated human embryonic kidney (HEK)293 cells [71]. Intriguingly,
such effects were not observed in similar experiments using vitamin K1 or K2 in these cells.
There are several possible reasons for this divergence in activity between the naphthoquinone
homologues. However, menadione is known to be inert as a co-factor for the vitamin K–
dependent gamma-carboxylation reaction [72], suggesting that alternative mechanisms,
related to their redox properties, rather than protein modification are likely to be more
dominant.
These researchers also found that menadione was capable of suppressing LPS-induced NF-
κB nuclear translocation and TNF-α release from murine macrophage-like RAW 264 cells [71].
Additionally, in a murine model of acute lung injury/acute respiratory distress syndrome
(ARDS), which occurs in the setting of acute severe illness complicated by systemic inflam-
mation, menadione also attenuated the LPS-induced severity of lung injury and suppressed
the increase in serum TNF-α level. This occurred concomitantly with inhibition the LPS-evoked
nuclear translocation of NF-κB in lung tissue.
Together, these data indicate that menadione has a capacity to ameliorate inflammation. The
in vivo examples identified above can be described as rigorous tests of the anti-inflammatory
potential of this molecule. The mechanism of action is likely to centre on NF-κB, but the strong
suppression of glucose-6-phosphate dehydrogenase in the rabbit arthritis model and, thereby,
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the regulation of intracellular NADPH, may indicate another important feature of the anti-
inflammatory character of menadione.
3.2.2. Inhibition of inflammation by a vitamin K catabolite, NaQuinate
Vitamin K1 and K2s are broken down in the liver, and this is the only organ that has been
reported to be responsible for the catabolism of these vitamins [73]. Early metabolism studies
in men using radioactive vitamin K1 has revealed the catabolites to be side-chain shortened
carboxylic acid products, the more abundant being a 5-carbon aliphatic acid, while the less
abundant is a 7-carbon aliphatic acid containing a single double bond (Figure 2) [74]. These
compounds are glucuronidated in the liver for excretion in the bile or through the kidneys. In
human studies, the level of the catabolites varies with the amount of vitamin K ingested at
pharmacological doses, as either phylloquinone or menaquinone-4 [75] or with dietary
phylloquinone intake [76].
We have found that both of these acid catabolites cannot participate in the gamma-carboxyla-
tion reaction and are, in fact, inhibitors or the vitamin K gamma-carboxylase enzyme (Soper
and Hodges, unpublished data).
Figure 2. The metabolism of vitamin K1 (A) and vitamins K2 (B) with the common generation is the 7-carbon carboxyl-
ic acid catabolite, NaQuinate (C), which is further broken down to the 5-carbon carboxylic acid catabolite (D).
Our recent studies with the 7-carbon carboxylic acid catabolite of vitamin K, NaQuinate
(Figure 1), found significant attenuation of LPS-challenged osteoblast-like MG63 cell IL-6
release [77]. This has likely in vivo implications, as in humans NaQuinate is usually present at
high levels following pharmacological vitamin K dosing, irrespective of the source of vitamin
K as either vitamin K1 or any of the vitamin K2 vitamers (Figure 2) [75]. Parallel experiments
in MG63 cells using 1,25-(OH)2-vitamin D3 or interleukin-1β as agonists showed similar
suppression of IL-6 release by NaQuinate (Soper and Hodges, unpublished data). Interestingly,
LPS-challenged MG63 cells were substantially less affected by the 5-carbon carboxylic acid
vitamin K catabolite (Figure 2), which only differs from NaQuinate by 2 carbon atoms and a
carbon-carbon double bond [77].
These results are in agreement with our earlier findings with LPS-challenged primary human
fibroblast cultures [56]. Furthermore, if the carboxylic acid function on the catabolites is
blocked with a methyl group, the LPS-induced release of IL-6 is greatly reduced in MG63 cells
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[77]. The reason for the disparity in inhibitory activities between the two closely related vitamin
K catabolites is not known, and a free acid function is a common structural element of many
widely used anti-inflammatory agents.
It should be noted that, in comparison to the descriptions above of the effects of vitamin K on
NF-κB and other anti-inflammatory markers, the concentration of NaQuinate required to
achieve an effect was substantially lower, with an IC50 of 2–5 × 10−7 M.
More recently, in vivo investigations have been performed using NaQuinate in two murine
models of bone loss, induced through either ovariectomy (OVx), or as a result of limb disuse
following sciatic neurectomy (NTx). In the OVx model, we found, using several micro-
computed tomography measurement parameters, that tibial trabecular bone loss was
significantly ameliorated in NaQuinate treated animals (0.75 mg/kg); the tibiae in the sham-
operated control group being indistinguishable from the NaQuinate-treated oviarectomised
animals [77]. We found that the more aggressive bone loss following NTx was also greatly
reduced in the NaQuinate-treated animals. Moreover, we found substantial reduction in the
inhibition of bone loss in both of the mouse models when a NaQuinate derivative containing
a methyl ester group was used to block the carboxylic acid function, suggesting that a free
carboxylic acid function is required for effective inhibition of bone loss in these models.
4. Concluding remarks
Vitamin K has been found to have anti-inflammatory activity in an increasing number of
studies. This inhibitory activity would appear to be directed through inhibition of NF-κB
signalling. In cell culture experiments, it is often mentioned that the cells needed to be primed
with vitamin K before being challenged with agonists. Furthermore, experimental results are
immerging that show inhibition of cytokine release in agonist-challenged cell culture and
animal models, which in the light of vitamin K deficiency in chronic diseases, may reflect on
a vitamin K role in organ homeostasis. Therefore, the defining vitamin K sufficiency on the
basis solely of adequate functional blood clotting factors is likely to be an over-simplification
and needs to be considered more fully.
The question is open as to the value of vitamin K in a therapeutic or a prophylactic role. For
example, a vitamin K deficient, seriously ill patient is unlikely to benefit greatly from a vitamin
K intervention, but a patient with a chronic inflammatory disease may. This can only be
highlighted in large community studies, which need to be run over many years in large
numbers of volunteers.
However, there are already some indications of prophylactic benefit of increased vitamin K
intake in large population studies in Japan. Exploring consumption of ‘natto’, a live menaqui-
none-7 producing bacteria (Bacillus subtilis subsp) culture food product from fermented
soybean that is culturally more favoured in the east than the west of Japan found that ingestion
substantially increases human circulating menaquinone-7 levels and that bacterial gut
colonization was evident several days after a single 80 g natto portion [78]. Intriguingly,
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prefectural sales of natto also linked consumption with a notable decrease in age-related hip
fractures in eastern Japanese population [78].
Given the safety of vitamin K, even in high pharmaceutical doses, supplementation may have
a benefit, beyond meeting coagulation demands than is generally perceived, particularly in
early chronic inflammatory diseases and inflammaging.
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